JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F–positive essential thrombocythemia
Juan Li(University of Cambridge), Anthony R. Green(Wellcome/MRC Cambridge Stem Cell Institute), Wendy N. Erber(The University of Western Australia), Katrin Ottersbach(MRC Centre for Regenerative Medicine), Peter J. Campbell(Wellcome Sanger Institute), Brian J.P. Huntly(Wellcome/MRC Cambridge Stem Cell Institute), Cédric Ghevaert(NHS Blood and Transplant), Philip Beer(Genoscience Pharma (France)), Rita Ferreira(University of Canberra), Dominik Spensberger(University of Cambridge), Linda M. Scott(University of Cambridge), Steve P. Watson(University of Nottingham), Jong Sook Ahn(University of Cambridge), Edwin Chen(University of Cambridge), Shubha Anand(University of Cambridge), Ariel Forrai(Walter and Eliza Hall Institute of Medical Research), Pentao Liu(Hong Kong Science and Technology Parks Corporation)
Cited by 203
Related Papers
COSMIC: the Catalogue Of Somatic Mutations In Cancer
|Nucleic Acids Research|2018|5.2k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
The cancer genome
|Nature|2009|3.5k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k